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Abstract. Background: Prostate cancer (PC) is a common
tumor in Western countries. Several risk factors play
significant roles. MYC, BIRC5/survivin, CDC25 and P53
may contribute to PC risk. As demonstrated, human
Polyomavirus BK (BKV) could affect cellular homeostasis
contributing to PC pathogenesis. Materials and Methods:
Biological samples were collected from PC patients. Viral
RNA was searched using quantitative polymerase chain
reaction (PCR), whereas a qualitative PCR was employed to
find particular viral sequences. Proper size amplicons were
analyzed. Single nucleotide polymorphisms (SNPs) were
detected in p53 coding regions by means of a specific PCR.
C-MYC, BIRC5/survivin and CDC25 gene expression was
investigated using a Retro Transcriptional Quantitative PCR.
Results: Viral DNA copy number was higher in cancer
tissues taken from Gleason score 9 patients with Gleason
score 7. Different p53 mutated compared to patients exons
were found according to tumor advanced stage and a
statistical significant correlation was found between Gleason
score and p53 mutational rate. C-MYC, BIRC5/survivin and
CDC25 expression was de-regulated according to the
literature. Conclusion: The presence of BKV and its variants
in transformed cells does not exclude viral pressure in cell
immortalization. Expression of other target genes evidenced
a significant change in their regulation, useful for cancer
drug discovery and therapies.
Prostate cancer (PC), a multi-factorial disease, is the most
common tumor in Western countries (1, 2). Although age is
the main risk factor, other factors, such as genes and
infections, play significant role (3, 4). A great number of
genes, such as MYC, BIRC5/survivin, CDC25 and P53 may
contribute to PC risk (5).
MYC mRNA has been found to be elevated in cancer
tissue with respect to matched benign prostatic hyperplasia
tissues in the majority of cases. Moreover, it has been
demonstrated that MYC amplification is related to PC
progression (6).
BIRC5, encoding for surviving, functions as a negative
regulator of apoptosis or programmed cell death. The protein
survivin is highly expressed in most human tumors and its
up-regulation has also been reported to possibly confer
hormone resistance in PC (7-9).
CDC25 is a dual-specificity phosphatase present in
mammalian cells in three forms named a, b and c (10).
Misregulation of CDC25a levels could lead to genomic
instability, a cancer hallmark. Furthermore, CDC25a over-
expression often correlates with more aggressive diseases
and poor prognosis (10).
P53 is a tumor suppressor gene whose mutations are
implicated in the molecular genetics of many malignancies.
Single-point mutations have been shown to not only abrogate
p53 function but also contribute to the transformed
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phenotype. Certain DNA viruses may also contribute to the
progression of invasive cancer in infected tissue acting to
p53. Viral oncoproteins interact with p53 inhibiting its action
(11). Inactivation of p53 has been proposed as the main
mechanism whereby the oncogenic human Polyomavirus BK
(BKV) plays a role in cancer progression (12). In the past,
our research group demonstrated the presence of BKV in PC
tissues suggesting that it could affect cellular homeostasis in
the prostate and play the role of a co-factor in PC
pathogenesis (13, 14). In particular, the viral large T antigen
(TAg) is able to interfere with p53 oncosuppressor blocking
apoptosis. Moreover, in laboratory animals, it has been
demonstrated that the BKV regulatory region (RR) affects,
in a sequence-dependent manner, cellular tropism and
oncogenicity. RR rearrangements are associated with higher
oncogenicity as a consequence of a more intense induction
of cell proliferation (15, 16).
Taking into account this molecular and oncoviral portrait,
the aim of the present study was to understand if normal
prostate cells are really susceptible to viral infection and if
BKV could play a role in a transformation scenario. In
addition, p53 mutational analyses were performed and the
expression pattern of selected PC genes was studied.
Materials and Methods
Patient population. From March 2012 to October 2013, 71 patients
(median age=63) without a history of neoplastic diseases were
admitted to the ‘‘Umberto I’’ Hospital of Rome, Italy, and enrolled
according to the following criteria: (i) no previous hormonal or
radiation therapy; (ii) no previous surgery on the prostate gland; (iii)
histologically proven prostate cancer by biopsy and confirmed by
radical prostatectomy;
Tumors were selected accounting for histopathological diagnosis,
tumor size, grade and stage, the androgen receptor status and family
history data.
Urine, blood and fresh tissue samples were collected from
patients with clinically proven pT2aN0M0 or pT3N0M0 prostate
adenocarcinoma. As controls, 71 non-tumor biopsies of the same
patients were analyzed.
BKV DNA was searched in urine, blood and fresh PC samples
by means of a quantitative polymerase chain reaction (Q-PCR).
BKV RNA corresponding to TAg was searched using a Retro
Transcriptional Quantitative PCR (RT-QPCR). Finally, BKV RR
was searched by nested PCR and sequenced (17).
The sequencing analysis of p53 specific DNA binding exons (5-
9) was carried out to understand if mutations might be correlated
with viral infection and/or cancer progression.
Moreover, other target genes (C-MYC, BIRC5/survivin, CDC25)
than P53, in PC gene profile, were considered. Genes were chosen
using the ONCOMINE database and scientific literature. Their
expression was investigated using RT-QPCR.
Processing of clinical specimens. DNA was extracted from 1 ml of
urine, 200 μl of plasma and about 25 mg of fresh PC resections
using the DNeasy® Tissue Kit (QIAGEN, S.p.A, Milan, Italy)
according to the manufacturer’s instructions.
RNA was extracted from biopsies using the Total RNA
Purification Kit (Norgen Biotek Corporation 3430, Thorold
Ontario Canada) according to supplier’s protocol. cDNA was
obtained by the iScript cDNA Synthesis Kit (BioRad Laboratories
S.r.l, Milan, Italy). One microgram of total purified DNA was used
for QPCR, whereas two micrograms of total purified cDNA were
used for RT-QPCR.
Q-PCR for BKV DNA and viral TAg cDNA. Urine, blood, fresh PC
and control specimens were tested using Q-PCR for detection of
BKV. Viral genome was quantified from each sample using a Q-PCR
Alert Kit (ELITechGroup S.p.A, Trezzano S/N, Milan, Italy) in a
7300 Real-Time PCR System (AB Applied Biosystem, Foster City,
CA, USA). Results for urine and plasma specimens were expressed as
copies of viral DNA per milliliter (c/ml) and as copies per 105 cells
(c/105 cells) for the biopsies. To correct the DNA variable amount in
different tissue samples, each sample was subjected to simultaneous
TaqMan PCR for the housekeeping gene Glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH, Accession No. J04038), targeting
the region between exons 6-8. Results were considered acceptable
only in the presence of GAPDH-positivity (18).
Q-PCR for C-MYC, BIRC5/survivin, CDC25. All reagents were
spinned for 10-15 sec, then, in a PCR tube, the following reagents
were added: 12.5 μl of RT2 SYBR Green Q-PCR Master Mix, 1.5 μl
of high-quality nuclease-free H2O, 10 μl of cDNA (template) and
1.0 μl of gene-specific RT2 Q-PCR specific primers. Tubes were
quickly centrifuged and placed in a 7300 Real Time PCR System
(AB Applied Biosystem, Foster City, CA, USA). Two-step cycling
program was used; thermal cycling was initiated with a first
denaturation step of 10 min at 95˚C followed by 40 cycles of 95˚C
for 15 s, 60˚C for 1 min. SYBR Green fluorescence from every well
was detected and recorded during the annealing step of each cycle.
Specific gene expression was quantified by using the 2-ΔΔCT
method (19). Normalization of gene expression was performed
using GAPDH as a reference gene.
PCR for BKV RR and amplicons sequencing. BKV RR was obtained
by nested PCR as previously described (17). Correct size amplicons
were purified prior to sequencing with QIAquick PCR purification kit
(QIAGEN, S.p.A, Milan, Italy). DNA sequencing was performed in
service (BioFab research s.r.l., Rome, Italy). Acquired sequences were
analyzed by the Basic Local Alignment Search Tool at the NCBI
website (http://blast.ncbi.nlm.nih.gov/Blast.cgi), whereas alignments
were performed with ClustalW2 at the EMBL-EBI website
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) using default parameters. 
Mutational analysis of P53. P53 mutational analysis was performed
according to Das and co-workers (12). Single nucleotide
polymorphisms (SNPs) were detected by means of specific PCR in
coding regions between exons 5-9. PCR products were separated by
1% agarose gel electrophoresis, purified (QIAquick PCR
purification kit; QIAGEN, S.p.A, Milan, Italy) and sequenced
(BioFab research s.r.l., Rome, Italy). Acquired sequences were
analyzed by the Basic Local Alignment Search Tool at the NCBI
website, whereas alignments were performed with ClustalW2 at the
EMBL-EBI website using default parameters.
P53 sequence used for alignments corresponds to the genomic
sequence NC_000017.10 (NCBI37/hg19, Chr17:7571720..7590917)
from GenBank.
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Data analysis. Data were summarized as medians and ranges or as
mean, as appropriate. If the Z test indicated a non-normal
distribution, nonparametric tests such as the Mann–Whitney U-test
and Kruskal–Wallis test, were used. Categorical data were analyzed
by using the χ2 test and Student's t-test. Values of p<0.05 were
considered statistically significant.
Results
Urine analysis revealed the presence of BKV genome in 6/71
(8%) patients, whereas 4/71 (6%) blood samples were
positive for viral DNA. The average number of viral copies
calculated in positive urine did not exceed 1,000 c/ml,
whereas this value was 475 c/ml in blood samples (Table I).
Examination of biopsies evidenced BKV DNA in 31/71
(44%) (Table I). The average number of viral copies was
calculated on biopsies of positive patients belonging to the
same Gleason score. Twelve patients with Gleason 9
showed an average of 16,000 c/105 cells, whereas in eight
patients with Gleason 8 an average of 12,500 c/105 cells
was found and, finally, nine patients with Gleason 7
showed an average of 8,364 c/105 cells (Table I).
Regarding patients with Gleason score 6, two patients were
BKV DNA-positive with a low mean copy number of 1,000
c/105 cells (Table I). No controls were found positive (data
not shown).
Regarding statistical analysis, the comparison between the
mean values of BKV DNA copy numbers obtained for each
class of Gleason scores over the months of this trial was not
statistically significant, although copy numbers decrease
from the class with the highest Gleason score (9) to that with
lower Gleason score (7) (Table I).
Regarding the P53 mutational analysis, all specimens had
at least one mutated exon. It was found that codons 248
(exon 7) and 273 (exon 8) were the most susceptible to
mutation (5, 20). Exon 7 was always mutated in patients with
Gleason score 9. Mutations in exons 5, 6, 8 and 9 were
observed in 12/31 positive specimens. The results are shown
in Table II.
It is known that mutations of P53 are rare in primary PC
but more common in PC at a higher tumor stage, higher
tumor grade, metastases or androgen-independent tumors.
Results confirmed these data and different mutated exons
were found according to tumor advanced stage (5). In
particular, statistical analysis proved a significant correlation
between Gleason score and the number of p53 mutated exons
(14).
In order to understand if PC cells present a particular
genotype, target genes C-MYC, BIRC5/survivin and CDC25
rather than P53 were considered. Genes were chosen using
the ONCOMINE database and scientific literature. Their
expression was investigated using RT-Q-PCR. According to
scientific production, results showed the up-regulation of
C-MYC at the mRNA level (Figure 1). De-regulated myc
levels contribute to tumor growth by metabolic re-
programming and by adaptation to the microenvironment
(21, 22).
Also survivin expression was enhanced in the analyzed
samples (Figure 1). According to molecular profiling studies,
high survivin expression in cancer has been correlated to
indicate overall survival, resistance to therapy and shorter
disease-free survival (23).
Regarding the CDC25 gene, results showed its over-
expression in cancer cells confirming its role as proto-
oncogene (Figure 1). Its increased transcription often
correlates with more aggressive diseases and poor prognosis,
as demonstrated by Ray and Kiyokawa (24).
To understand if prostate cells are really non-permissive
cells for BKV replication, searching of viral messengers was
performed. In particular, since TAg is required to support
viral DNA replication, its mRNA was investigated.
Messenger amount was too low to allow replication (data not
shown). The use of fresh samples proved essential for
consistent and reproducible amplification of viral DNA,
nevertheless to ratify the source of the signal detected by
PCR, viral infection of human prostate cancer cell lines
DU145 and PC3 is mandatory. These lines are not hormone-
sensitive, do not express prostate specific antigen (PSA) and
differ for their metastatic potential.
Finally, an interesting role in cancer development could be
played by RR rearrangements. In this study, two RR variants
were found in two patients affected by Gleason 9 prostate
cancer (Figure 2). These variants were characterized by
enhancement of the oncogenic c-myc and the oncosuppressor
p53 binding sites.
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Table I. Average number of viral copies calculated in BKV-positive samples.
Urine Blood Biopsies 
Positive BKV samples 6/71 (8%) 4/71 (6%) 31/71 (44%) 
Average of viral copies number 1000 c/ml 475 c/ml Gleason 9: 16,000 c/105 cells 
Gleason 8: 12,500 c/105 cells 
Gleason 7: 8,364 c/105 cells 
Gleason 6: 1,000 c/105 cells 
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Table II. An example of multiple sequence alignment for P53 gene (exon 5).
Table II. continued
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Table II. An example of multiple sequence alignment for P53 gene (exon 6).
Table II. An example of multiple sequence alignment for P53 gene (exon 7).
Table II. continued
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Table II. An example of multiple sequence alignment for P53 gene (exon 9).
Table II. An example of multiple sequence alignment for P53 gene (exon 8).
Discussion
PC is the most frequent cancer in men (1-4). Genetic
background may contribute to PC risk. In fact, MYC,
BIRC5/survivin, CDC25 and P53 genes are the ones most
often implicated and investigated for the specific desease (5).
Exposure to infectious agents has been reported to have a
putative role in tumorigenesis. Among the infectious agents,
several lines of evidence converge on the oncogenic human
Polyomavirus BK (25, 26).
BKV’s role in cancer is controversial (14, 26-28). Tumors
of the urinary tract are the most logical target for an
etiological association with BKV, since this urotheliotropic
virus persists indefinitely as 'latent' in the kidney and urinary
system (15).
This study investigated the presence of BKV sequences in
urine, blood and fresh PC specimens from radical
prostatectomies by means of a quantitative PCR assay.
The presence of detectable viral DNA assesses that
persistent infection could contribute to cancer progression.
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Figure 1. Expression of C-MYC, BIRC5/survivin and CDC25 genes in all biopsies analyzed. Data were expressed as copies out of 105 cells.
According to scientific production, results showed that expression for all genes was up-regulated.
Figure 2. Schematic representation of BKV RR variants found in samples taken from two patients affected by Gleason 9 prostate cancer. These
variants were characterized by enhancement of the oncogenic c-myc and the oncosuppressor p53 binding sites. RR of the proposed archetypal BK
strain WW has been arbitrarily divided into five blocks containing the origin of DNA replication (O-block) and four blocks (P, Q, R and S)
encompassing binding sequences of cellular transcription factors. These sequences are involved in transcriptional regulation of viral genes. In
particular, in no permissive cells, RR undergoes a rearrangement process allowing for selection of viral variants with a transformation potential.
Although BKV DNA copy numbers obtained for each class
of Gleason scores during this investigation was not
statistically significant, it is conceivable to speculate that
BKV could promote development of tumors cooperating
with cellular proteins for a complete ‘‘neoplastic phenotype’’
and progression of metastatic disease. Moreover, it cannot be
excluded that low levels of messengers detected could be
translated in low copies of protein able to interfere with
control of cell replication conferring the infected cells
properties characteristics of cancer, such as loss of growth
control. In fact, in no permissive cells, BKV activates the
cellular DNA replication machinery and other genes involved
in S-phase progression; however, virions are not produced.
This aberrant stimulation could contribute to an oncogenic
transformation. Moreover, TAg, preparing the cellular
metabolism to support optimal viral replication, de-regulates
the cell’s control cycle pathways inducing cell proliferation.
Nevertheless, it is clear that, in their natural hosts, tumor
induction derives from a combination of circumstances and
is not a part of the normal virus life cycle (15).
DNA sequencing analysis of p53 exons (5-9) was carried
out to estimate its mutational rate and to understand if
mutations might be correlated with viral infection and/or
cancer progression. It is known that SNP not only abrogate
p53 function but are commonly revealed in PC at a higher
tumor stage, higher tumor grade, metastases or androgen-
independent tumors (5, 20). In this study, the presence of
different mutated exons was found in agreement to tumor
advanced stage. In fact, according to the literature, it was
found that codons 249 (exon 7) and 273 (exon 8) were more
susceptible to mutation for all patients (5, 20). In particular,
exon 7 was always mutated in patients with higher Gleason
tumor score (Gleason 9). Regarding the possible link
between P53 mutations and BKV infection, it is intriguing
to hypothesize that, in heterozygote subjects for P53 gene
mutations, the poor quantity of wild type protein could be
sequestered from viral TAg promoting the development of a
neoplastic phenotype. Therefore, BKV may play a role in the
progression of PC rather than in its onset.
An interesting oncogenic role could be played by viral RR
rearrangements. In this study, two interesting variants were
found since they are characterized by an implementation of
binding sites for oncosuppressor p53 and oncoprotein c-myc
(Figure 2). In no permissive cells, binding sites for
oncoproteins or tumor suppressors could be selected to
promote cell proliferation; thus, rearrangements could
enhance the transformation potential of the virus. For
example, c-myc could be bound by virus to prevent its
accumulation into the cell that, otherwise, would be
eliminated through protective apoptosis. Alternatively, p53
could be sequestered either by TAg either by viral RR to
block its role as the “guardian of the genome”. In any case,
RR rearrangements probably represent adaptive changes
conferring increased “viral fitness” in the host-cell
environment.
Finally, C-MYC, BIRC5/survivin and CDC25 expression
was investigated.
The finding increased C-MYC mRNA could be related to
PC progression or metastatization, since in normal cells this
messenger has a short half-life (about 30 min). Hence,
understanding the role of c-Myc in PC is important to yield
insights that might be of therapeutic importance.
Similarly to Myc, survivin can be regarded as an oncogene
as its aberrant over-expression in most cancers contributes to
a phenotype more resistant to apoptotic stimuli and
chemotherapeutic therapies allowing continued proliferation
and survival. P53's normal function is to regulate genes that
control apoptosis. As survivin is a known inhibitor of
apoptosis, it can be implied that P53-induced repression of
survivin is one mechanism by which cells can undergo
apoptosis upon induction by apoptotic stimuli or signals (29).
When loss of wild-type P53 occurs, survivin is over-expressed
in the cells, thus contributing to cancer progression.
The Cdc25 phosphatases function as key regulators of the
cell cycle during normal eukaryotic cell division and as
mediators of the checkpoint response in cells Cdk/cyclin
complexes. Their role in cancer onset is more complicated
than that of a simple driver of cell proliferation. It is possible
to hypothesize that Cdc25 over-expression in tumors is
required to circumvent the checkpoints that would otherwise
hinder cell proliferation.
In conclusion, data underline that specific target genes could
be a molecular marker for early detection of certain cancers. In
particular, understudying how their expression could be edited
on changes of their regulators (i.e. the signal transducers and
activators of transcription) it is of great importance for cancer
drug discovery and therapies. About BKV, DNA presence does
not exclude viral pressure on cell transformation. In particular
the presence of RR variants allows hypothesizing that they
could modify cell expression profile aiding immortalization.
However, more studies are necessary to ascertain how to use
expression of gene patterns for cancer therapy and how BKV
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